CervoMed completes Phase 2a trial enrollment for rare frontotemporal dementia candidate

• The Phase 2a clinical study of oral neflamapimod successfully completed enrollment with 25 active patients.
• The clinical program evaluates safety, localized pharmacokinetics, and speech-language clinical effects.
• Interim biological data readouts are officially scheduled for presentation at the CTAD 2026 conference.

CervoMed (NASDAQ:CRVO), a clinical-stage biotechnology company focused on treating age-related brain disorders, announced today that it has finalized patient enrollment for its Phase 2a clinical trial evaluating its lead drug candidate, neflamapimod, in individuals with nonfluent variant primary progressive aphasia (nfvPPA).

The specialized 25-patient open-label study is designed to evaluate the safety, target engagement pharmacokinetics, and initial clinical language efficacy of two distinct oral dosing strategies: 40 mg administered three times daily (n=19) and 80 mg administered twice daily (n=6).

NfvPPA is a progressive form of frontotemporal dementia (FTD) that gradually destroys communication pathways, leading to halting, highly effortful speech expression while leaving basic word comprehension intact.

It currently affects an estimated 10,000 to 15,000 individuals in the United States alone, with zero approved medical treatments available on the market.

Moving forward, the company plans to present preliminary interim biomarker and fluid data during the Clinical Trials on Alzheimer's Disease (CTAD) conference in Madrid, Spain, scheduled for late 2026.

Comprehensive top-line clinical and speech-assessment data from the fully enrolled cohort are slated for release during the first quarter of 2027.